| Name | Title | Contact Details |
|---|
Proteolix, Inc. is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O`Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.
Redwood Toxicology Laboratory is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.